Instead of designing a novel sterile connection system, which is risky, Ori Biotech miniaturized and multiplexed the proven "paper pull tab" system. This approach leverages a trusted, decades-old technology to build reliability and gain acceptance for their innovative automation platform.
To handle delicate primary cells, Ori Biotech designed a single bellows-based bioreactor that operates in multiple modes: static (T-flask), rocked (wave reactor), or with low-shear plunging (stirred tank). This flexibility allows optimization of different process steps like activation, transduction, and expansion within the same container.
The true scalability problem in cell therapy isn't just manufacturing but the mountains of paperwork for QA/QC. Ori Biotech's solution is a fully digitized ecosystem that captures every action, sensor reading, and integrates analytical equipment results directly into a cloud-based digital batch record.
To make hospital-based manufacturing feasible, complex material preparation (e.g., thawing and formulating viruses) must be eliminated. Ori Biotech's model allows partners to pre-fill consumables at a central facility. These are then shipped frozen and ready-to-use, de-skilling the process at the point of care.
Despite clinical success, cell and gene therapy pipelines are stunted. The core issue is a broken business model, where therapies are difficult to distribute globally and profitably. A scalable manufacturing platform is the key to enabling profitability, which in turn fuels reinvestment into new therapies.